Published February 14, 2026 | Version v1
Journal article Open

REVIEW ON SOLUBILITY ENHANCEMENT TECHNIQUES IN PHARMACEUTICAL FORMULATIONS

Authors/Creators

  • 1. India
  • 2. India.

Description

Poor aqueous solubility is a major challenge in pharmaceutical formulation development, as it directly affects drug dissolution, absorption, and bioavailability. A significant proportion of newly developed drug molecules exhibit low water solubility, leading to formulation difficulties and reduced therapeutic effectiveness. To address this issue, a wide range of solubility enhancement techniques have been explored and implemented in pharmaceutical sciences. This review provides a comprehensive overview of conventional, advanced, and emerging approaches used to enhance the solubility of poorly water-soluble drugs in pharmaceutical formulations. Various physical, chemical, and formulation-based strategies such as particle size reduction, solid dispersion, salt formation, pH adjustment, complexation, surfactant-based systems, lipid-based drug delivery systems, nanotechnology-based approaches, and other novel techniques are discussed. Additionally, alternative and supportive approaches including hydrotropy, amorphization, electrospinning, and the use of solubilizing excipients are highlighted. Understanding the principles, advantages, and limitations of these techniques is essential for selecting an appropriate solubility enhancement strategy and for improving the clinical performance of poorly soluble drugs. This review aims to serve as a valuable reference for researchers, formulators, and students involved in pharmaceutical formulation development.

Files

39 WJPSR 2065.pdf

Files (529.6 kB)

Name Size Download all
md5:f2fdc381132f13764e23477a45e16e2a
529.6 kB Preview Download

Additional details

References

  • 1. Savjani KT, Gajjar AK, Savjani JK. Drug solubility: importance and enhancement techniques. ISRN Pharm, 2012; 2012: 195727. doi:10.5402/2012/195727.
  • 2. Serajuddin AT. Salt formation to improve drug solubility. Adv Drug Deliv Rev, 2007; 59(7): 603–616. doi:10.1016/j.addr.2007.07.008.
  • 3. Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins: basic science and product development. J Pharm Pharmacol, 2010; 62(11): 1607–1621. doi:10.1111/j.2042-7158.2010.01167.x.
  • 4. Chiou WL, Riegelman S. Pharmaceutical applications of solid dispersion systems. J Pharm Sci., 1971; 60(9): 1281–1302. doi:10.1002/jps.2600600911.
  • 5. Vasconcelos T, Sarmento B, Costa P. Solid dispersions as strategy to improve oral bioavailability of poorly water-soluble drugs. Drug Discov Today, 2007; 12(23–24): 1068–1075. doi:10.1016/j.drudis.2007.09.005.
  • 6. Van den Mooter G. The use of amorphous solid dispersions: a formulation strategy to overcome poor solubility. J Pharm Pharmacol, 2012; 64(12): 157–170. doi:10.1111/j.2042-7158.2012.01469.x.
  • 7. Müller RH, Gohla S, Keck CM. State of the art of nanocrystals—special features and production. Eur J Pharm Biopharm, 2011; 78(1): 1–9. doi:10.1016/j.ejpb.2011.03.008.
  • 8. Singh BN, Kim KH. Nanotechnology for enhancing solubility and bioavailability of poorly water-soluble drugs. Int J Pharm, 2013; 453(1): 3–12. doi:10.1016/j.ijpharm.2013.05.013.
  • 9. Porter CJH, Trevaskis NL, Charman WN. Lipid-based formulations as a strategy to enhance oral bioavailability. Nat Rev Drug Discov, 2007; 6(3): 231–248. doi:10.1038/nrd2167.
  • 10. Constantinides PP, Wasan KM. Lipid formulations for oral administration of poorly water-soluble drugs. Adv Drug Deliv Rev, 2007; 59(7): 677–694. doi:10.1016/j.addr.2007.07.011.
  • 11. Gupta P, Vermani K, Garg S. Hydrotropy: an overview. Pharm Dev Technol, 2004; 9(1): 1–10. doi:10.1080/10837450490264962.
  • 12. Dixit N, Nagarsenker MS. Solubilization of poorly soluble drugs by polymeric micelles. Pharm Dev Technol, 2008; 13(3): 323–330. doi:10.1080/10837450802086408.
  • 13. Stegemann S, Leveiller F, Friesen D, et al. When poor solubility becomes an issue. Eur J Pharm Sci., 2007; 31(5): 249–261. doi:10.1016/j.ejps.2007.06.003.
  • 14. Sinha VR, Kumria R. Solid dispersion formulations for enhancing bioavailability. Int J Pharm, 2004; 272(1–2): 1–10. doi:10.1016/j.ijpharm.2003.12.004.
  • 15. Rades T, York P. Design of amorphous solid dispersions. Pharm Res, 1997; 14(6): 708–714. doi:10.1023/A:1012129828135.
  • 16. Quan P, Gao Y, Liu Y. Mesoporous silica nanoparticles for drug solubility enhancement. Drug Dev Ind Pharm, 2014; 40(5): 589–600. doi:10.3109/03639045.2013.853660.
  • 17. Christopher Vimalson D, Parimalakrishnan S, Jeganathan NS, Anbazhagan S. Techniques to enhance solubility of hydrophobic drugs. Asian J Pharm, 2016; 10(2): S67–S75. doi:10.4103/ajp.ajp_221_15.
  • 18. Kesharwani SS, Bhat GJ. Nanotechnology-based solubility enhancement strategies. Medicina, 2020; 56(11): 557. doi:10.3390/medicina56110557.
  • 19. Pawar SR, Barhate SD. Solid dispersion: a novel boon to increase bioavailability. J Drug Deliv Ther, 2019; 9(2): 243–247. doi:10.22270/jddt.v9i2.2437.
  • 20. Narmada I. Contemporary review on solubility enhancement techniques. J Drug Deliv Ther, 2023; 13(2): 5944. doi:10.22270/jddt.v13i2.5944.
  • 21. Dhande LB. Solubility enhancement by solid dispersion method. J Drug Deliv Ther, 2023; 11(1): 4489. doi:10.22270/jddt.v11i1.4489.
  • 22. Sharma A, Chaudhary A, Singh B. Solubility enhancement by solid dispersion technique. J Pharm Res Int., 2021; 33(63A): 77–87. doi:10.9734/jpri/2021/v33i63A35217.
  • 23. Kumar MS, Rajesh M, Subramanian L. Solubility enhancement techniques: a comprehensive review. World J Biol Pharm Health Sci., 2023; 13(3): 141–149. doi:10.30574/wjbphs.2023.13.3.0125.
  • 24. Borgaonkar VB, Jain CM, Jaiswal AR. Solubility enhancement techniques for pharmaceutical drugs. GSC Biol Pharm Sci., 2024; 26(2): 239–253. doi:10.30574/gscbps.2024.26.2.0069.
  • 25. Shelke PS, Waghmare SU, Suryawanshi RK. Review on solubility enhancement techniques. Int J Pharm Pharm Sci., 2024; 6(1): 144–148. doi:10.33545/26647222.2024.v6.i1b.113.
  • 26. Savolainen J, Rantanen J, Yliruusi J. Prediction of drug solubility from physicochemical properties. Int J Pharm., 2003; 263(1–2): 45–53. doi:10.1016/S0378-5173(03)00225-9.
  • 27. Porter CJH, Pouton CW, Cuine JF, Charman WN. Enhancing intestinal drug solubilisation using lipid-based delivery systems. Adv Drug Deliv Rev., 2008; 60(6): 673–691. doi:10.1016/j.addr.2007.10.014.
  • 28. Dressman JB, Reppas C. In vitro–in vivo correlations for lipophilic drugs. Eur J Pharm Sci., 2000; 11: S73–S80. doi:10.1016/S0928-0987(00)00181-9.
  • 29. Aulton ME, Taylor KMG. Aulton's Pharmaceutics: The Design and Manufacture of Medicines. 5th ed. Elsevier; 2018.
  • 30. Qiu Y, Chen Y, Zhang GGZ, Liu L, Porter WR. Developing Solid Oral Dosage Forms. 2nd ed. Academic Press; 2017.
  • 31. Yadav VB, Yadav AV. Enhancement of solubility and dissolution rate of poorly water-soluble drugs. Int J Pharm Sci Res., 2015; 6(2): 417–430. doi:10.13040/IJPSR.0975-8232. 6(2).417-30.